Commercializing BiomarkersTherapeutic and Diagnostic Market
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Consumables
1.2.3 Services
1.2.4 Software
1.3 Market by Application
1.3.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Neurology
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Perspective (2017-2028)
2.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Growth Trends by Region
2.2.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Historic Market Size by Region (2017-2022)
2.2.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Region (2023-2028)
2.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Dynamics
2.3.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry Trends
2.3.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Drivers
2.3.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Challenges
2.3.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players by Revenue
3.1.1 Global Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players by Revenue (2017-2022)
3.1.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Players (2017-2022)
3.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue
3.4 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Concentration Ratio
3.4.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in 2021
3.5 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Key Players Head office and Area Served
3.6 Key Players Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Solution and Service
3.7 Date of Enter into Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Breakdown Data by Type
4.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Historic Market Size by Type (2017-2022)
4.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Type (2023-2028)
5 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Breakdown Data by Application
5.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Historic Market Size by Application (2017-2022)
5.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2017-2028)
6.2 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type
6.2.1 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2017-2022)
6.2.2 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2023-2028)
6.2.3 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Type (2017-2028)
6.3 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application
6.3.1 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2017-2022)
6.3.2 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2023-2028)
6.3.3 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Application (2017-2028)
6.4 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country
6.4.1 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2017-2022)
6.4.2 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2017-2028)
7.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type
7.2.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2017-2022)
7.2.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2023-2028)
7.2.3 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Type (2017-2028)
7.3 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application
7.3.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2017-2022)
7.3.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2023-2028)
7.3.3 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Application (2017-2028)
7.4 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country
7.4.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2017-2022)
7.4.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2017-2028)
8.2 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type
8.2.1 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Type (2017-2028)
8.3 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application
8.3.1 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Application (2017-2028)
8.4 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region
8.4.1 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2017-2028)
9.2 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type
9.2.1 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2017-2022)
9.2.2 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2023-2028)
9.2.3 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Type (2017-2028)
9.3 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application
9.3.1 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2017-2022)
9.3.2 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2023-2028)
9.3.3 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Application (2017-2028)
9.4 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country
9.4.1 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2017-2022)
9.4.2 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2017-2028)
10.2 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type
10.2.1 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Type (2017-2028)
10.3 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application
10.3.1 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Application (2017-2028)
10.4 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country
10.4.1 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.1.4 Roche Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
11.1.5 Roche Recent Developments
11.2 Dako (Agilent Technologies)
11.2.1 Dako (Agilent Technologies) Company Details
11.2.2 Dako (Agilent Technologies) Business Overview
11.2.3 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.2.4 Dako (Agilent Technologies) Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
11.2.5 Dako (Agilent Technologies) Recent Developments
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.3.4 Merck Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
11.3.5 Merck Recent Developments
11.4 BD
11.4.1 BD Company Details
11.4.2 BD Business Overview
11.4.3 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.4.4 BD Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
11.4.5 BD Recent Developments
11.5 Abbott
11.5.1 Abbott Company Details
11.5.2 Abbott Business Overview
11.5.3 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.5.4 Abbott Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
11.5.5 Abbott Recent Developments
11.6 Genesys Biolabs (20/20GeneSystems)
11.6.1 Genesys Biolabs (20/20GeneSystems) Company Details
11.6.2 Genesys Biolabs (20/20GeneSystems) Business Overview
11.6.3 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.6.4 Genesys Biolabs (20/20GeneSystems) Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
11.6.5 Genesys Biolabs (20/20GeneSystems) Recent Developments
11.7 Affymetrix
11.7.1 Affymetrix Company Details
11.7.2 Affymetrix Business Overview
11.7.3 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.7.4 Affymetrix Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
11.7.5 Affymetrix Recent Developments
11.8 Agendia
11.8.1 Agendia Company Details
11.8.2 Agendia Business Overview
11.8.3 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.8.4 Agendia Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
11.8.5 Agendia Recent Developments
11.9 ALMAC
11.9.1 ALMAC Company Details
11.9.2 ALMAC Business Overview
11.9.3 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.9.4 ALMAC Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
11.9.5 ALMAC Recent Developments
11.10 Arrayit
11.10.1 Arrayit Company Details
11.10.2 Arrayit Business Overview
11.10.3 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.10.4 Arrayit Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
11.10.5 Arrayit Recent Developments
11.11 Biocartic
11.11.1 Biocartic Company Details
11.11.2 Biocartic Business Overview
11.11.3 Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.11.4 Biocartic Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
11.11.5 Biocartic Recent Developments
11.12 BG Medicine
11.12.1 BG Medicine Company Details
11.12.2 BG Medicine Business Overview
11.12.3 BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.12.4 BG Medicine Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
11.12.5 BG Medicine Recent Developments
11.13 KEGG EXPRESSION Database
11.13.1 KEGG EXPRESSION Database Company Details
11.13.2 KEGG EXPRESSION Database Business Overview
11.13.3 KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.13.4 KEGG EXPRESSION Database Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
11.13.5 KEGG EXPRESSION Database Recent Developments
11.14 Thermo Fisher
11.14.1 Thermo Fisher Company Details
11.14.2 Thermo Fisher Business Overview
11.14.3 Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.14.4 Thermo Fisher Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
11.14.5 Thermo Fisher Recent Developments
11.15 BGI
11.15.1 BGI Company Details
11.15.2 BGI Business Overview
11.15.3 BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.15.4 BGI Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
11.15.5 BGI Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Consumables
Table 3. Key Players of Services
Table 4. Key Players of Software
Table 5. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 6. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (2017-2022) & (US$ Million)
Table 8. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Region (2017-2022)
Table 9. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 10. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Region (2023-2028)
Table 11. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Trends
Table 12. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Drivers
Table 13. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Challenges
Table 14. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Restraints
Table 15. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Players (2017-2022) & (US$ Million)
Table 16. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Share by Players (2017-2022)
Table 17. Global Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications as of 2021)
Table 18. Ranking of Global Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies by Revenue (US$ Million) in 2021
Table 19. Global 5 Largest Players Market Share by Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (CR5 and HHI) & (2017-2022)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Solution and Service
Table 22. Date of Enter into Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2017-2022) & (US$ Million)
Table 25. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Type (2017-2022)
Table 26. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 27. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Type (2023-2028)
Table 28. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2017-2022) & (US$ Million)
Table 29. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Share by Application (2017-2022)
Table 30. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 31. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Share by Application (2023-2028)
Table 32. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2017-2022) & (US$ Million)
Table 33. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2023-2028) & (US$ Million)
Table 34. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2017-2022) & (US$ Million)
Table 35. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2023-2028) & (US$ Million)
Table 36. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2017-2022) & (US$ Million)
Table 37. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2023-2028) & (US$ Million)
Table 38. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2017-2022) & (US$ Million)
Table 39. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2023-2028) & (US$ Million)
Table 40. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2017-2022) & (US$ Million)
Table 41. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2023-2028) & (US$ Million)
Table 42. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2017-2022) & (US$ Million)
Table 43. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2023-2028) & (US$ Million)
Table 44. Asia Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2017-2022) & (US$ Million)
Table 45. Asia Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2023-2028) & (US$ Million)
Table 46. Asia Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2017-2022) & (US$ Million)
Table 47. Asia Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2023-2028) & (US$ Million)
Table 48. Asia Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (2017-2022) & (US$ Million)
Table 49. Asia Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (2023-2028) & (US$ Million)
Table 50. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2017-2022) & (US$ Million)
Table 51. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2023-2028) & (US$ Million)
Table 52. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2017-2022) & (US$ Million)
Table 53. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2023-2028) & (US$ Million)
Table 54. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2017-2022) & (US$ Million)
Table 55. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2023-2028) & (US$ Million)
Table 56. Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2017-2022) & (US$ Million)
Table 57. Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Type (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Application (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2023-2028) & (US$ Million)
Table 62. Roche Company Details
Table 63. Roche Business Overview
Table 64. Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 65. Roche Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022) & (US$ Million)
Table 66. Roche Recent Developments
Table 67. Dako (Agilent Technologies) Company Details
Table 68. Dako (Agilent Technologies) Business Overview
Table 69. Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 70. Dako (Agilent Technologies) Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022) & (US$ Million)
Table 71. Dako (Agilent Technologies) Recent Developments
Table 72. Merck Company Details
Table 73. Merck Business Overview
Table 74. Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 75. Merck Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022) & (US$ Million)
Table 76. Merck Recent Developments
Table 77. BD Company Details
Table 78. BD Business Overview
Table 79. BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 80. BD Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022) & (US$ Million)
Table 81. BD Recent Developments
Table 82. Abbott Company Details
Table 83. Abbott Business Overview
Table 84. Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 85. Abbott Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022) & (US$ Million)
Table 86. Abbott Recent Developments
Table 87. Genesys Biolabs (20/20GeneSystems) Company Details
Table 88. Genesys Biolabs (20/20GeneSystems) Business Overview
Table 89. Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 90. Genesys Biolabs (20/20GeneSystems) Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022) & (US$ Million)
Table 91. Genesys Biolabs (20/20GeneSystems) Recent Developments
Table 92. Affymetrix Company Details
Table 93. Affymetrix Business Overview
Table 94. Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 95. Affymetrix Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022) & (US$ Million)
Table 96. Affymetrix Recent Developments
Table 97. Agendia Company Details
Table 98. Agendia Business Overview
Table 99. Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 100. Agendia Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022) & (US$ Million)
Table 101. Agendia Recent Developments
Table 102. ALMAC Company Details
Table 103. ALMAC Business Overview
Table 104. ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 105. ALMAC Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022) & (US$ Million)
Table 106. ALMAC Recent Developments
Table 107. Arrayit Company Details
Table 108. Arrayit Business Overview
Table 109. Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 110. Arrayit Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022) & (US$ Million)
Table 111. Arrayit Recent Developments
Table 112. Biocartic Company Details
Table 113. Biocartic Business Overview
Table 114. Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 115. Biocartic Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022) & (US$ Million)
Table 116. Biocartic Recent Developments
Table 117. BG Medicine Company Details
Table 118. BG Medicine Business Overview
Table 119. BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 120. BG Medicine Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022) & (US$ Million)
Table 121. BG Medicine Recent Developments
Table 122. KEGG EXPRESSION Database Company Details
Table 123. KEGG EXPRESSION Database Business Overview
Table 124. KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 125. KEGG EXPRESSION Database Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022) & (US$ Million)
Table 126. KEGG EXPRESSION Database Recent Developments
Table 127. Thermo Fisher Company Details
Table 128. Thermo Fisher Business Overview
Table 129. Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 130. Thermo Fisher Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022) & (US$ Million)
Table 131. Thermo Fisher Recent Developments
Table 132. BGI Company Details
Table 133. BGI Business Overview
Table 134. BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product
Table 135. BGI Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022) & (US$ Million)
Table 136. BGI Recent Developments
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Type: 2021 VS 2028
Figure 2. Consumables Features
Figure 3. Services Features
Figure 4. Software Features
Figure 5. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Application: 2021 VS 2028
Figure 6. Oncology Case Studies
Figure 7. Cardiology Case Studies
Figure 8. Neurology Case Studies
Figure 9. Other Case Studies
Figure 10. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Report Years Considered
Figure 11. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 12. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Region: 2021 VS 2028
Figure 14. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Players in 2021
Figure 15. Global Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications as of 2021)
Figure 16. The Top 10 and 5 Players Market Share by Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in 2021
Figure 17. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY (2017-2028) & (US$ Million)
Figure 18. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Market Share by Type (2017-2028)
Figure 19. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Market Share by Application (2017-2028)
Figure 20. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Share by Country (2017-2028)
Figure 21. United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Canada Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY (2017-2028) & (US$ Million)
Figure 24. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Market Share by Type (2017-2028)
Figure 25. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Market Share by Application (2017-2028)
Figure 26. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Share by Country (2017-2028)
Figure 27. Germany Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. France Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. U.K. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Italy Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Russia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Nordic Countries Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY (2017-2028) & (US$ Million)
Figure 34. Asia Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Market Share by Type (2017-2028)
Figure 35. Asia Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Market Share by Application (2017-2028)
Figure 36. Asia Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Share by Region (2017-2028)
Figure 37. China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. South Korea Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Southeast Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. India Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Australia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY (2017-2028) & (US$ Million)
Figure 44. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Market Share by Type (2017-2028)
Figure 45. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Market Share by Application (2017-2028)
Figure 46. Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Share by Country (2017-2028)
Figure 47. Mexico Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Brazil Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 49. Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY (2017-2028) & (US$ Million)
Figure 50. Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Market Share by Type (2017-2028)
Figure 51. Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Market Share by Application (2017-2028)
Figure 52. Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Share by Country (2017-2028)
Figure 53. Turkey Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. Saudi Arabia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. UAE Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 56. Roche Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
Figure 57. Dako (Agilent Technologies) Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
Figure 58. Merck Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
Figure 59. BD Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
Figure 60. Abbott Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
Figure 61. Genesys Biolabs (20/20GeneSystems) Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
Figure 62. Affymetrix Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
Figure 63. Agendia Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
Figure 64. ALMAC Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
Figure 65. Arrayit Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
Figure 66. Biocartic Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
Figure 67. BG Medicine Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
Figure 68. KEGG EXPRESSION Database Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
Figure 69. Thermo Fisher Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
Figure 70. BGI Revenue Growth Rate in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2017-2022)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
